← boardnext 2026-09
CGEM
Cullinan Therapeutics Inc.distress 1/10 · well-funded / low risk$17.21-2%today-7% from 52w high
Oncology 4
Lead: relapsed/refractory AML · target PD-1
Revenue
pre-revenue
Liquidity
$390M
Runway
2.2 yrs
Shares 1y
+4%
Price & events
+36.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.5%
1D
+4.9%
1W
-3.0%
1M
+32.9%
3M
+37.7%
6M
+106.6%
1Y
-17.5%
2Y
-33.3%
5Y
-42.5%
All
Overview
- Market Cap
- $1.06B
- Volume
- 36.32K
- 52 Week Range
- $5.75 – $18.48
- Total Shares
- 61.46M
- Float Shares
- 44.16M
- Short %
- 24.47%
- % Held by Insiders
- 0.45%
- % Held by Institutions
- 107.69%
- RVOL
- 0.03x
- Beta
- -0.01
Pipeline stages · 1 programs
CLN-049
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 6 trials · 3 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-09 Estimated 50% readout ~2026-10-01 final ~2027-03-31 | Phase 1 | CLN-619fast track | Multiple Myeloma | 30 | active not recruiting |
| 2026-11 Estimated 50% readout ~2026-12-01 | Phase 1 | CLN-978fast track | NHL, NHL, Relapsed, Adult | — | active not recruiting |
| 2027-01 Estimated 50% readout ~2027-01-31 | Phase 1 | CLN-049fast track | Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) | — | recruiting |
| 2026-06-16 | Phase 1 | CLN-617, Pembrolizumabfast track | Advanced Solid Tumor | 23 | terminated |
| 2026-03 | Phase 1 | CLN-619, Pembrolizumab, Paclitaxelfast track | Advanced Solid Tumor, NSCLC | 440 | active not recruiting |
Show all 6 trials · 1 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2025-10-13 | Phase 1/2 | CLN-081fast track | Non Small Cell Lung Cancer, EGFR Exon 20 Mutation | 284 | active not recruiting |
Upcoming readouts & decisions · our signals
1 upcoming event has our read — the sell-the-news timing call plus an experimental clinical estimate. Go Pro to see them.
Catalyst news & presentations · 19
- first quarter of 2027Guided 70%trial initiationsecondaryPhase 1/2Velinotamig · Phase 1/2a trial initiation.SEC 8-K
- early 2027Guided 55%trial initiationsecondaryPhase 2CLN-978 · Phase 2a expansion trial initiation.SEC 8-K
- fourth quarter of 2026Guided 70%readoutPhase 1/2Velinotamig · Additional multi-dose regimen data readout.SEC 8-K
- fourth quarter of 2026Guided 70%enrollment completesecondaryPhase 1CLN-049 · Complete enrollment for dose expansionSEC 8-K
- fourth quarter of 2026Guided 70%trial initiationsecondaryPhase 1/2CLN-049 · Initiate Phase 1/2 combination studySEC 8-K
- fourth quarter of 2026Guided 70%readoutPhase 1CLN-978 · Additional multi-dose regimen data readout.SEC 8-K
- third quarter of 2026Guided 70%readoutPhase 1CLN-978 · Additional multi-dose regimen data readout.SEC 8-K
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
- second quarter of 2026readoutPhase 1CLN-978 · Initial data from Part ASEC 8-K
- first half of 2026enrollment completesecondaryzipalertinib · Complete enrollment of pivotal REZILIENT3 study.SEC 8-K
- second quarter of 2026trial initiationsecondaryPhase 1CLN-049 · Initiate monotherapy dose expansion cohortsSEC 8-K
- 2026-06-10conferencedata presentationsecondaryPhase 1/2Velinotamig · Initial clinical data presentation from Phase 1b/2a trial in China.SEC 8-K
- first quarter of 2026regulatory submissionFiled (NDA/BLA)Zipalertinib · Completion of rolling NDA submissionSEC 8-K
- December 2025conferencedata presentationsecondaryPhase 1CLN-049 · Oral presentation of Phase 1 data (~30% CRc rate in AML).SEC 8-K
- by YE 2025regulatory submissionFiled (NDA/BLA)zipalertinib · Potential NDA filing by TaihoSEC 8-K
- IASLC 2025 WCLCconferencedata presentationsecondaryPhase 2zipalertinib · Updated data from REZILIENT1 Phase 2bSEC 8-K
- end of this yeartrial initiationsecondaryPhase 1velinotamig · Genrix to initiate Phase 1 study in ChinaSEC 8-K
- 2025-06-04partnershipvelinotamig · Global exclusive license from Genrix BioSEC 8-K
- 2024-10-16fda agreementCLN-978 · FDA cleared IND for Phase 1 trial in moderate to severe SLESEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $32 (+83% upside) · 11 analysts
- 2026-06-11WedbushOutperform
- 2026-06-08HC Wainwright & Co.Buy
- 2026-05-19BTIGBuy
- 2026-05-08WedbushOutperform
- 2026-05-04BTIGBuy
- 2026-04-28BTIGBuy
Competitors — PD-1
- REGNREGENERON PHARMACEUTICALS, INC.$60.4B · D2
- BEIGFBeOne Medicines Ltd.$31.7B · D1
- NCNANuCana plc$28.3B · D2
- EXELEXELIXIS, INC.$13.8B · D0
- TNGXTango Therapeutics, Inc.$4.0B · D5
- IOVAIOVANCE BIOTHERAPEUTICS, INC.$2.3B · D4
- REPLReplimune Group, Inc.$906M · D2
- ALXOALX ONCOLOGY HOLDINGS INC$262M · D5
- BCABBioAtla, Inc.$107M · D8
- IOBTQIO Biotech, Inc.$71,949 · D5
Recent news
- 2026-07-17Why (CGEM) Price Action Is Critical for Tactical Trading - Stock Traders Daily
- 2026-07-16CGEM Q1 2026 Earnings: Smaller Loss Than Expected as Pipeline Progress Continues - EPS Consistency Score - dars.gov.et
- 2026-07-15CGEM Q1 2026 Earnings: Narrower Net Loss Exceeds Expectations as Clinical Progress Continues - High Growth Earnings - dars.gov.et
- 2026-07-14CGEM Q1 2026 Earnings: EPS Beat on Lower Operating Costs as Cullinan Advances Pipeline - Tangible Book Value - dars.gov.et
- 2026-07-11CGEM Q1 2026 Earnings: EPS Beat Estimates Despite Pre-Revenue Status - Earnings Whisper Number - Bölüm Sonu Canavarı
- 2026-07-11CGEM Q1 2026 Earnings: EPS Beat Estimates Despite Pre-Revenue Status - Revenue Growth Outlook - dars.gov.et
- 2026-07-09CGEM Q1 2026 Earnings: EPS Beat Drives Modest Stock Gain as Pipeline Progress Continues - Revenue Surprise History - dars.gov.et
- 2026-07-07Cullinan CSO sells shares, exercises options | CGEM Insider Trading - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.